Breo Ellipta 25 ug/1

Breo Ellipta 25 ug/1 is a respiratory medication combining fluticasone furoate and vilanterol trifenatate. It is designed for inhalation use to manage chronic respiratory conditions. This powder-based inhaler is manufactured by GlaxoSmithKline LLC in the USA.

Breo Ellipta 25 ug/1 is primarily used for the maintenance treatment of chronic obstructive pulmonary disease (COPD) and asthma. This combination medication works by reducing inflammation and relaxing the airways, making it easier to breathe. It is often prescribed for individuals who require both an inhaled corticosteroid and a long-acting beta-agonist for effective symptom management.

Common effects of Breo Ellipta 25 ug/1 may include throat irritation, headache, and hoarseness. Some users might experience a mild increase in heart rate or tremors. These effects are generally mild and temporary, but persistent or severe reactions should be discussed with a healthcare provider.

Breo Ellipta 25 ug/1 should be used as directed by a healthcare professional. It is important to follow the prescribed dosage and administration instructions. Patients with certain medical conditions, such as heart disease or diabetes, should use this medication with caution. Always store the inhaler in a cool, dry place and keep it out of reach of children.

Breo Ellipta 25 ug/1 may interact with other medications, including beta-blockers, diuretics, and certain antidepressants. It is advisable to inform your healthcare provider about all medications you are taking to avoid potential interactions. Additionally, the use of alcohol or other respiratory depressants should be discussed with a healthcare professional.